Dizal Pharma

Dizal Pharma (Dizal (Jiangsu) Pharmaceutical Co., Ltd.) is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines in oncology and immunology. Originating in 2017 from research capabilities established in China, the company operates research and development across Shanghai and Wuxi (Jiangsu), China, and is listed on the Shanghai Stock Exchange STAR Market (ticker 688192). Dizal's most advanced programs include sunvozertinib (DZD9008), an oral EGFR exon 20 insertion inhibitor for non-small cell lung cancer marketed as Zegfrovy, and golidocitinib (DZD4205), a selective JAK1 inhibitor developed for relapsed/refractory peripheral T-cell lymphoma. Dizal Pharma was surfaced in the API Evangelist network as a portfolio company of the venture firm HongShan (formerly Sequoia Capital China). As a pharmaceutical developer it publishes a corporate marketing and investor-facing website but does not expose a public developer platform, API program, or machine-readable API artifacts at this time; this profile captures the company identity for the network.

Dizal Pharma is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Pharmaceutical, Biotechnology, and Oncology.

Dizal Pharma’s developer surface includes engineering blog and 5 more developer resources.

🌐 Visit website 📡 Source on GitHub

8.1/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyHealthcarePharmaceuticalBiotechnologyOncologyImmunologyDrug DevelopmentClinical ResearchLife Sciences

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 8.1/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.4 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/dizal-pharma: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Company 4

The organization behind the API

Website

About

Blog

Careers

Source (apis.yml)

aid: dizal-pharma
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/dizal-pharma.png
name: Dizal Pharma
description: Dizal Pharma (Dizal (Jiangsu) Pharmaceutical Co., Ltd.) is a clinical-stage biopharmaceutical company focused
  on discovering and developing novel medicines in oncology and immunology. Originating in 2017 from research capabilities
  established in China, the company operates research and development across Shanghai and Wuxi (Jiangsu), China, and is listed
  on the Shanghai Stock Exchange STAR Market (ticker 688192). Dizal's most advanced programs include sunvozertinib (DZD9008),
  an oral EGFR exon 20 insertion inhibitor for non-small cell lung cancer marketed as Zegfrovy, and golidocitinib (DZD4205),
  a selective JAK1 inhibitor developed for relapsed/refractory peripheral T-cell lymphoma. Dizal Pharma was surfaced in the
  API Evangelist network as a portfolio company of the venture firm HongShan (formerly Sequoia Capital China). As a pharmaceutical
  developer it publishes a corporate marketing and investor-facing website but does not expose a public developer platform,
  API program, or machine-readable API artifacts at this time; this profile captures the company identity for the network.
url: https://raw.githubusercontent.com/api-evangelist/dizal-pharma/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- hongshan
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Healthcare
- Pharmaceutical
- Biotechnology
- Oncology
- Immunology
- Drug Development
- Clinical Research
- Life Sciences
apis: []
common:
- type: DomainSecurity
  url: security/dizal-pharma-domain-security.yml
- type: Website
  url: https://www.dizalpharma.com
- type: About
  url: https://www.dizalpharma.com/about
- type: Blog
  url: https://www.dizalpharma.com/news
- type: Careers
  url: https://www.dizalpharma.com/careers
- type: Contact
  url: https://www.dizalpharma.com/contact
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence

Dizal Pharma

Kin Score

Security Posture 1

Dizal Pharma Domain Security

Resources

Access & Security 1

Operate 1

Company 4

Source (apis.yml)